$0.34 EPS Expected for Sucampo Pharmaceuticals, Inc. (SCMP)

February 15, 2018 - By Hazel Jackson

 $0.34 EPS Expected for Sucampo Pharmaceuticals, Inc. (SCMP)
Investors sentiment increased to 1.65 in Q3 2017. Its up 0.32, from 1.33 in 2017Q2. It increased, as 14 investors sold Sucampo Pharmaceuticals, Inc. shares while 40 reduced holdings. 31 funds opened positions while 58 raised stakes. 29.83 million shares or 20.72% more from 24.71 million shares in 2017Q2 were reported.
11,653 are owned by Ahl Ltd Liability Partnership. Los Angeles Cap Management & Equity Research holds 0% or 17,553 shares in its portfolio. Moreover, Serv Automobile Association has 0% invested in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Pinnacle holds 0% of its portfolio in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) for 11,600 shares. Rhumbline Advisers holds 0% of its portfolio in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) for 50,350 shares. 201,538 were reported by Dana Inv Advisors. 112,170 are owned by Gsa Prtn Limited Liability Partnership. 15,350 were reported by Thrivent Finance For Lutherans. Tiaa Cref Ltd Liability Corporation accumulated 96,676 shares or 0% of the stock. Lsv Asset Mgmt stated it has 2.47M shares or 0.05% of all its holdings. Hightower Advisors Lc invested in 0.01% or 119,847 shares. Palisade Mgmt Limited Liability Corporation Nj reported 0.01% in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Invesco holds 63,860 shares or 0% of its portfolio. Nationwide Fund has 0% invested in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) for 32,008 shares. Numeric Invsts Ltd Liability Co reported 107,700 shares stake.

Since September 11, 2017, it had 0 buys, and 3 selling transactions for $24.83 million activity. 50,000 shares were sold by Kiener Peter A, worth $825,000 on Thursday, December 7. $12.00 million worth of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) shares were sold by Ueno Ryuji.

Analysts expect Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) to report $0.34 EPS on March, 14.They anticipate $0.34 EPS change or 50.00 % from last quarter’s $0.68 EPS. SCMP’s profit would be $16.01M giving it 13.24 P/E if the $0.34 EPS is correct. After having $0.27 EPS previously, Sucampo Pharmaceuticals, Inc.’s analysts see 25.93 % EPS growth. It closed at $18 lastly. It is down 5.30% since February 15, 2017 and is downtrending. It has underperformed by 22.00% the S&P500.

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) Ratings Coverage

Among 13 analysts covering Sucampo Pharma (NASDAQ:SCMP), 4 have Buy rating, 0 Sell and 9 Hold. Therefore 31% are positive. Sucampo Pharma had 46 analyst reports since August 6, 2015 according to SRatingsIntel. The firm has “Outperform” rating by Northland Capital given on Wednesday, September 7. The rating was maintained by Mizuho with “Hold” on Wednesday, January 3. The firm has “Buy” rating by UBS given on Thursday, October 12. The firm has “Neutral” rating by Mizuho given on Friday, January 15. The firm has “Hold” rating by Mizuho given on Wednesday, November 1. The firm has “Buy” rating by Mizuho given on Thursday, December 22. Maxim Group maintained Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) rating on Wednesday, August 26. Maxim Group has “Buy” rating and $25 target. The company was maintained on Wednesday, August 16 by Jefferies. Mizuho upgraded the stock to “Buy” rating in Wednesday, April 20 report. The stock has “Buy” rating by H.C. Wainwright on Monday, August 24.

Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing, identifying, acquiring, and marketing medicines that meet unmet medical needs, primarily in gastroenterology, ophthalmology, and oncology-related disorders in the United States, Japan, Switzerland, and internationally. The company has market cap of $847.54 million. The company's marketed product includes AMITIZA , a ClC-2 chloride channel activator for the treatment of chronic idiopathic constipation (CIC) in adults, irritable bowel syndrome with constipation in adult women (IBS-C), and opioid-induced constipation (OIC)in patients with chronic non-cancer related pain; and RESCULA (unoprostone isopropyl), a big potassium channel activator for the treatment of glaucoma and ocular hypertension. It currently has negative earnings. The Company’s product candidates in clinical development stage comprise Lubiprostone that is in Phase III clinical trials for the treatment of pediatric functional constipation and (IBS-C); and completed Phase III clinical trials for the treatment of (CIC) in adults, IBS-C in adult women, and OIC in patients with chronic non-cancer pain, as well as CPP-1X/sulindac combination product, which has completed Phase III clinical trials for the treatment of familial adenomatous polyposis.

More important recent Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) news were published by: Prnewswire.com which released: “Monteverde & Associates PC Files Class Action Lawsuit On Behalf Of …” on January 25, 2018, also Bizjournals.com published article titled: “Sucampo Pharmaceuticals closes on its $1.2B sale to a UK company”, Bizjournals.com published: “Shareholders sue Sucampo, claim proposed sale undervalues the company” on February 05, 2018. More interesting news about Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) was released by: Prnewswire.com and their article: “Mallinckrodt Completes Acquisition Of Sucampo Pharmaceuticals, Inc.” with publication date: February 13, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.